Gene therapy has become a promising strategy for the treatment of many inheritable or
acquired diseases that are currently considered incurable. Non-viral vectors have attracted …

The continually increasing wealth of knowledge about the role of genes involved in acquired
or hereditary diseases renders the delivery of regulatory genes or nucleic acids into affected …

Potent sequence selective gene inhibition by siRNA 'targeted'therapeutics promises the
ultimate level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake …

During the past decade, RGD-peptides have become a popular tool for the targeting of
drugs and imaging agents to αvβ3-integrin expressing tumour vasculature. RGD-peptides …

Gene therapy has long sought to treat disease by delivering therapeutic genes to diseased
cells. However, its widespread clinical use has faltered in the face of several challenges …

Importance of the field: The targeted delivery of therapeutic agents to tumour cells is a
challenge because most of the chemotherapeutic agents distribute to the whole body, which …

Tumor-targeting DNA complexes which can readily be generated by the mixing of stable
components and freeze− thawed would be very advantageous for their subsequent …

The ability to deliver nucleic acids (eg, plasmid DNA, antisense oligonucleotides, siRNA)
offers the potential to develop potent vaccines and novel therapeutics. However, nucleic …

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new
methods of drug delivery and pharmaceuticals have been investigated in vitro, and in …

Background Targeting to integrin receptor ανβ3 by RGD peptides seems to be a promising
approach for gene delivery to proliferating endothelial cells of tumor metastases. PEGylation …